Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 6/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.55 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.55 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.53 |
| ▸ | P2RY14 | Q15391 | 6/20 | 0.52 |
| ▸ | TMEM97 | Q5BJF2 | 5/20 | 0.51 |
| ▸ | DRD5 | P21918 | 4/20 | 0.51 |
| ▸ | ADRB3 | P13945 | 4/20 | 0.51 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.51 |
| ▸ | DRD1 | P21728 | 3/20 | 0.51 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.51 |
| ▸ | HTR1A | P08908 | 2/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.51 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.51 |
| ▸ | DRD3 | P35462 | 2/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.51 |
| ▸ | PDE2A | O00408 | 1/20 | 0.51 |
| ▸ | PDE5A | O76074 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | INSR | P06213 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL381390 | 0.98 | HTR2C (1.00) | HTR2CSIGMAR1SLC18A3PTPN5P2RY14 | |
| SCHEMBL16660400 | 0.89 | HTR2C (0.79) | HTR2CP2RY14TMEM97HTR2A | |
| SCHEMBL1811550 | 0.89 | HTR2C (0.79) | HTR2CP2RY14TMEM97HTR2A | |
| SCHEMBL17938547 | 0.89 | HTR2C (0.79) | HTR2CP2RY14TMEM97HTR2A | |
| Trifluoroacetic Acid SCHEMBL2303613 | 0.88 | HTR2C (0.78) | HTR2CSIGMAR1SLC18A3P2RY14TMEM97 | |
| Hydrochloric Acid SCHEMBL31615877 | 0.88 | HTR2C (0.81) | HTR2CSIGMAR1SLC18A3PTPN5P2RY14 | |
| Hydrochloric Acid SCHEMBL4573167 | 0.87 | HTR2C (0.80) | HTR2CP2RY14TMEM97HTR2A | |
| SCHEMBL1847401 | 0.85 | HTR2C (0.73) | HTR2C | |
| SCHEMBL8047163 | 0.85 | HTR2C (0.73) | HTR2CSIGMAR1SLC18A3PTPN5P2RY14 | |
| SCHEMBL13543084 | 0.84 | HTR2C (0.72) | HTR2CSIGMAR1SLC18A3PTPN5P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10034892-B2 | Composition and methods of use of small molecules as binding ligands for the modulation of proprotein convertase subtilisin/kexin type 9(PCSK9) protein activity | SRX CARDIO, LLC (US) | 2018-07-31 | — | — | US | claimed |
| US-20170246196-A1 | COMPOSITION AND METHODS OF USE OF SMALL MOLECULES AS BINDING LIGANDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9(PCSK9) PROTEIN ACTIVITY | SRX CARDIO, LLC (US) | 2017-08-31 | — | — | US | claimed |
| EP-3182971-A1 | COMPOSITION AND METHODS OF USE OF SMALL MOLECULES AS BINDING LIGANDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9(PCSK9) PROTEIN ACTIVITY | SRX Cardio, LLC (US) | 2017-06-28 | — | — | EP | claimed |
| WO-2016029037-A1 | COMPOSITION AND METHODS OF USE OF SMALL MOLECULES AS BINDING LIGANDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9(PCSK9) PROTEIN ACTIVITY | SRX CARDIO, LLC (US) | 2016-02-25 | — | — | WO | claimed |
| US-20240122951-A1 | METHOD TO TREAT LIPID DYSREGULATION BY MODULATING ACTIVITY OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) PROTEIN WITH SMALL MOLECULE LIGANDS | SRX CARDIO, LLC | 2024-04-18 | — | — | US | disclosed |
| US-11820767-B2 | Benzyl amine-containing heterocyclic compounds and compositions useful against mycobacterial infection | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2023-11-21 | — | — | US | disclosed |
| US-11820767-B2 | Benzyl amine-containing heterocyclic compounds and compositions useful against mycobacterial infection | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2023-11-21 | — | — | US | disclosed |
| US-11771710-B2 | Method to treat lipid dysregulation by modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9) protein activity with small molecule ligands | SRX CARDIO, LLC (US) | 2023-10-03 | — | — | US | disclosed |
| US-11771710-B2 | Method to treat lipid dysregulation by modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9) protein activity with small molecule ligands | SRX CARDIO, LLC (US) | 2023-10-03 | — | — | US | disclosed |
| US-11771710-B2 | Method to treat lipid dysregulation by modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9) protein activity with small molecule ligands | SRX CARDIO, LLC (US) | 2023-10-03 | — | — | US | disclosed |
| US-20230089247-A1 | NOVEL COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA | ZYDUS LIFESCIENCES LIMITED (IN) | 2023-03-23 | — | — | US | disclosed |
| EP-4081509-A1 | NOVEL COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA | Zydus Lifesciences Limited (IN) | 2022-11-02 | — | — | EP | disclosed |
| US-5789402-A | Compounds having effects on serotonin-related systems | ELI LILLY COMPANY (US) | 1998-08-04 | — | — | US | disclosed |
| US-5741789-A | HETERO-OXY ALKANAMINES | ELI LILLY AND COMPANY (US) | 1998-04-21 | — | — | US | disclosed |
| US-5627196-A | ANTIDEPRESSANTS AND ANTISEROTONIN AGENTS | ELI LILLY AND COMPANY (US) | 1997-05-06 | — | — | US | disclosed |
| US-5614523-A | INDOLYLOXY COMPOUNDS | ELI LILLY AND COMPANY (US) | 1997-03-25 | — | — | US | disclosed |
| US-5576321-A | ALKOXY-SUBSTITUTED INDOLES | ELI LILLY AND COMPANY (US) | 1996-11-19 | — | — | US | disclosed |
| WO-1996022290-A1 | COMPOUNDS HAVING EFFECTS ON SEROTONIN-RELATED SYSTEMS | ELI LILLY AND COMPANY (US) | 1996-07-25 | — | — | WO | disclosed |
| EP-0722941-A2 | Compounds having effects on serotonin-related systems | ELI LILLY AND COMPANY (US) | 1996-07-24 | — | — | EP | disclosed |
| US-3936464-A | HYPOTENSIVE | AMERICAN CYANAMID COMPANY (US) | 1976-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11820767-B2 | Benzyl amine-containing heterocyclic compounds and compositions useful against mycobacterial infection | BET1, BRD4, BRD3 | HTR2C 3573/4885SIGMAR1 3175/4885SLC18A3 3789/4885 |
| US-20170246196-A1 | COMPOSITION AND METHODS OF USE OF SMALL MOLECULES AS BINDING LIGANDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9(PCSK9) PROTEIN ACTIVITY | PCSK9, LDLR, PCSK7 | HTR2C 3890/4885SIGMAR1 3522/4885SLC18A3 4361/4885 |
| US-10034892-B2 | Composition and methods of use of small molecules as binding ligands for the modulation of proprotein convertase subtilisin/kexin type 9(PCSK9) protein activity | PCSK9, LDLR, PCSK7 | HTR2C 3890/4885SIGMAR1 3522/4885SLC18A3 4361/4885 |
| US-20230089247-A1 | NOVEL COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA | PCSK9, CETP, LCAT | HTR2C 3892/4885SIGMAR1 3746/4885SLC18A3 2485/4885 |
| US-20240122951-A1 | METHOD TO TREAT LIPID DYSREGULATION BY MODULATING ACTIVITY OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) PROTEIN WITH SMALL MOLECULE LIGANDS | PCSK9, LDLR, PCSK7 | HTR2C 4074/4885SIGMAR1 3366/4885SLC18A3 4472/4885 |
| US-11771710-B2 | Method to treat lipid dysregulation by modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9) protein activity with small molecule ligands | PCSK9, LDLR, PCSK7 | HTR2C 4041/4885SIGMAR1 3312/4885SLC18A3 4480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.